Hunger Game: Hengrui Hunts New Cancer Drug With $200m BeyondSpring Tie-up

Hengrui’s second major in-licensing deal this year is the latest example of the Chinese pharma innovation darling’s eagerness for new assets, particularly as some of its other products come under pressure.